# US 8,465,748 B2 · Vaccine compositions and methods containing an immunogen derived from equine arteritis virus > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,465,748 B2 - Document ID: US8465748B2 - Status: Granted - Kind: B2 - Application number: 12/730,618 - Filed: 2010-03-24 - Published: 2010-09-30 - Granted: 2013-06-18 - Earliest claimed: 2009-03-30 - Applicants: Matthias Giese - Inventors: Matthias Giese - Web page: https://patentgrep.com/patent/US8465748B2 ## CPC - C07K 16/10: RNA viruses - A61K 39/12: Viral antigens - A61P 31/14: for RNA viruses - C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) - A61K 2039/53: {DNA (RNA) vaccination} - A61K 2039/552: {Veterinary vaccine} - A61K 2039/55533: {IL-2} - C12N 2770/10034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein - C12N 2770/10051: Methods of production or purification of viral material - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract The present invention relates to vaccine compositions comprising a nucleic acid encoded by an equine arterivirus virus (EAV) open reading frame (ORF) 2 nucleic acid, and a nucleic vector comprising said EAV ORF 2. The invention further relates to the methods and kits encompassing the use of EAV ORF 2 containing vaccine compositions and nucleic acid vectors for the prevention and/or treatment of EAV infections. ## Claims ### Claim 1 A nucleic acid vaccine composition that is protective against the Arteriviridae family and induces a cellular immune response, said vaccine encodes only one equine arteritis virus (EAV) protein consisting of open reading frame (ORF) 2 or 2b, wherein the coding sequence for ORF 2 or 2b is SEQ ID NO:1 or SEQ ID NO:2, wherein said vaccine composition is administered as a single base immunization without a booster, or as a base immunization followed by a first boost after 8-12 weeks, or as a base immunization followed by a first boost after 8-12 weeks and a second boost after 12 months. ### Claim 2 (depends on 1) The vaccine composition according to claim 1, wherein said nucleic acid is cDNA. ### Claim 3 (depends on 1) The vaccine composition according to claim 1, wherein said vaccine composition comprises one or several nucleic acid vectors each encoding the EAV sequence of claim 1. ### Claim 4 (depends on 3) The vaccine composition according to claim 3, wherein said nucleic acid vector(s) is/are expression vector(s). ### Claim 5 (depends on 4) The vaccine composition according to claim 4, wherein said expression vector(s) comprise(s) a eukaryotic cis-acting transcription/translation sequence functionally linked to the EAV sequence(s). ### Claim 6 (depends on 5) The vaccine composition according to claim 5, wherein said expression vector(s) is/are selected from the group of pCR3.1, pcDNA3.I/His A, pcDNA3.1/His B, pcDNA3.1/His C, and pDisplay (pD). ### Claim 7 (depends on 1) The vaccine composition according to claim 1, further comprising a nucleic acid encoding interleukin 2(IL-2) or a vector or expression vector comprising said nucleic acid encoding IL-2. ### Claim 8 (depends on 1) The vaccine composition according to claim 1, further comprising a pharmaceutically acceptable carrier or excipient. ### Claim 9 (depends on 1) The vaccine composition according to claim 1, further comprising one or several adjuvants selected from the group of Muramyl Dipeptide (MDP), Montanide 720, Poly Inosine:Cytosine (Poly I:C) or plasmid DNA comprising unmethylated cytosine, guanine dinucleotide sequence motifs (CpG). ### Claim 10 (depends on 1) The vaccine composition according to claim 1, further comprising: (a) an expression vector comprising a nucleic acid encoding IL-2; and (b) a carrier, an excipient or an adjuvant. ### Claim 11 (depends on 1) The vaccine composition according to claim 1, wherein the nucleic acid is encapsulated into cationic liposomes. ### Claim 12 (depends on 1) A method for prevention and/or treatment of EAV infection in a horse, comprising injecting a vaccine composition according to claim 1 into muscular cells of the horse in vivo; inducing a protective or therapeutic immune response in said horse upon or after exposure to EAV; and monitoring the reduction of EAV-associated symptoms or the reduction of horizontal or vertical transmission. ### Claim 13 (depends on 12) The method of claim 12, further comprising: coating the vaccine composition onto carrier particles; and accelerating the coated carrier particles into epidermal cells of the horse in vivo. ### Claim 14 (depends on 1) A kit comprising a vaccine composition according to claim 1 which is protective and/or therapeutic against infections mediated by an Arteriviridae virus in an animal, wherein said vaccine composition or one or more nucleic acid vector(s) induces a protective and/or therapeutic immune response following administration as a single base immunization without a booster, or as a base immunization followed by a first boost after 8-12 weeks, or as a base immunization followed by a first boost after 8-12 weeks and a second boost after 12 months. ### Claim 15 (depends on 14) The kit according to claim 14, wherein said Arteriviridae virus is selected from the group consisting of equine arteritis virus (EAV), porcine reproductive and respiratory syndrome virus (PRRSV), and simian haemorrhagic fever virus (SHFV).